New Dietary Ingredients: When Your Supplement Needs an NDI Notification

Most launch timelines don’t break at the fill line. They break the day someone asks a question that should have been asked at the start: is that ingredient actually cleared to go into a supplement? For a certain kind of ingredient (a novel botanical extract, a synthesized compound, a fashionable new active with a story but not much history), the honest answer can be a 75-day premarket notification to the FDA, backed by a safety dossier that takes months to assemble. Discover that after your formula is locked and your materials are on order, and you haven’t hit a speed bump. You’ve hit the wall. This is how to tell whether your ingredient is a “new dietary ingredient,” what the notification actually involves, and (the part that saves launches) how to surface it before it costs you anything.

Educational overview: not legal, regulatory, or medical advice. Requirements change and vary by jurisdiction and sales channel. Last reviewed July 2026.

Short answer: A new dietary ingredient (NDI) is a dietary ingredient that was not marketed in the United States before October 15, 1994. Under the Federal Food, Drug, and Cosmetic Act, a supplement containing one is deemed adulterated unless the ingredient either (1) has been present in the food supply as a food, in a form not chemically altered, or (2) is the subject of a premarket safety notification filed with FDA at least 75 days before it enters interstate commerce. So there are really three buckets: not new (pre-1994, “grandfathered”), new-but-exempt (already in the food supply, unaltered), and new-and-notify (everything else). The notification is not an approval, and there is no official list of grandfathered ingredients: the burden of proof sits with you.

Best for: Founders and brands building a product around a novel, imported, or newly popular ingredient.

Key decision: Which of the three buckets your ingredient falls into, and surfacing that before formulation and materials lock, not after.

Apollo path: Apollo flags a possible NDI at feasibility, before the bench commits, so your regulatory counsel can make the call while there’s still time. We support; your counsel decides. Request a Manufacturing Quote → /quote

One boundary up front, because it matters more here than almost anywhere: this explains how the NDI framework works; it is not legal advice, and whether a specific ingredient is “new,” “grandfathered,” or exempt is a fact-specific determination for your regulatory counsel. Apollo raises the flag early and coordinates; your counsel decides.

What makes a dietary ingredient “new”

The whole framework turns on one date. Under section 413 of the Federal Food, Drug, and Cosmetic Act (codified at 21 U.S.C. 350b, and verified against the current statute as of mid-2026), a new dietary ingredient is “a dietary ingredient that was not marketed in the United States before October 15, 1994.” That date is not arbitrary: it’s the day the Dietary Supplement Health and Education Act (DSHEA) was enacted, the law that built the modern supplement category. Everything already on the market that day was, in effect, allowed to stay. Everything introduced after it has to answer for itself.

Two words in that definition do quiet work, and both are worth pulling apart.

First, “dietary ingredient.” The NDI question only arises for something that is a dietary ingredient at all. The statute (21 U.S.C. 321(ff)) defines the category narrowly: a vitamin, a mineral, an herb or other botanical, an amino acid, a dietary substance for use by humans to supplement the diet by increasing total dietary intake, or a concentrate, metabolite, constituent, extract, or combination of any of those. If a substance doesn’t fit that list, it has a different and often harder problem: it may not be a lawful supplement ingredient by any path. The NDI process is the road for things that are dietary ingredients but are new ones.

Second, “marketed in the United States before October 15, 1994.” This is a factual claim about commercial history, and it is your claim to prove. It isn’t enough that an ingredient is ancient, used abroad, or rooted in traditional practice; it has to have been marketed as a dietary ingredient, in the United States, before that specific date. An herb used for centuries elsewhere but not sold here as a supplement ingredient until 2015 is, for this purpose, brand new.

The three buckets every ingredient falls into

Here is the decision the search results bury under legalese, laid out the way a formulator actually needs it. Any dietary ingredient you’re considering lands in exactly one of three buckets, and the bucket decides whether a 75-day notification stands between you and your launch.

The structure comes straight from the statute. Section 350b(a) says a supplement containing a new dietary ingredient “shall be deemed adulterated under section 342(f)” (the adulteration provision) unless it meets one of two requirements: the ingredient has been present in the food supply as a food, unaltered; or a safety notification is filed at least 75 days ahead. Add the pre-1994 ingredients that aren’t “new” at all, and you get three clean categories:

This is the framework, not a self-clearance tool. Which bucket a specific ingredient falls into, especially the middle one, is a fact-specific legal call. Route it to your counsel.

Notice what the table does and doesn’t say. Two of the three buckets require no filing, which is why most ingredients on most supplements never trigger a notification. But each no-filing bucket carries a burden of proof founders routinely underestimate, and the third carries a timeline most launch plans never budgeted for. The rest of this piece is about not being surprised by any of the three.

The grandfather trap: “it’s been around forever” is not a filing

The first bucket looks like the easy one. If your ingredient was marketed in the US before October 15, 1994, it isn’t a new dietary ingredient, and you owe FDA nothing. Plenty of common ingredients (long-established vitamins, minerals, and familiar botanicals) sit comfortably here.

The trap is that “grandfathered” is a documentation status, not an assumption. And there is a fact about it that catches brands flat: there is no official, authoritative FDA list of pre-1994 dietary ingredients. FDA has said so plainly, and it has gone a step further: it does not accept an ingredient’s inclusion on an industry list of “old dietary ingredients” as proof that the ingredient is not an NDI. Trade associations have compiled such lists; FDA’s position, as of mid-2026, is that it can’t verify them and won’t treat them as evidence on their own.

So the burden sits with you. If you’re relying on pre-1994 status, you should be able to show that the ingredient, in the form you’re using, was genuinely marketed as a dietary ingredient in the United States before that date: catalogs, invoices, labels, sales records, dated literature. FDA can ask, and “everyone knows it’s old” is not an answer that survives the question. This is the quiet failure mode: a brand assumes an ingredient is grandfathered, builds the product, and only later learns it can’t document the history, at which point it’s back to the third bucket, mid-launch, with a notification it never planned for.

The honest move is to decide early which ingredients you’re treating as grandfathered and confirm the documentation exists before you rely on it, not to discover the gap after the label prints.

“But it’s already in food”: why GRAS or food-additive status doesn’t settle it

The second bucket is the subtle one, and it’s where confident founders get tripped by a reasonable-sounding assumption: my ingredient is in food, or it’s GRAS, so a supplement is obviously fine. Sometimes that’s right. Often it isn’t, and the reason is worth understanding.

The exemption in the statute is specific. A new dietary ingredient does not require notification when it “has been present in the food supply as an article used for food in a form in which the food has not been chemically altered.” Read it slowly, because every clause is a condition:

• “Present in the food supply as an article used for food.” The ingredient itself has to have been used as food, not merely approved for some use, not used as food somewhere else in the world, but present in the US food supply as a food.
• “In a form in which the food has not been chemically altered.” This is the clause that does the damage. Take an ingredient that was an ordinary food, then process it (concentrate it, extract specific constituents, change its chemical form), and you can process your way out of the exemption. At that point it’s a new dietary ingredient that needs a notification, even though it started as food.

Two common misreadings deserve a direct answer. GRAS status for use in conventional food is not the same as the NDI food-supply exemption. An ingredient can be “generally recognized as safe” for a food use and still be a new dietary ingredient when it goes into a supplement, because GRAS-for-food doesn’t establish that the ingredient, in your form, qualifies under section 350b(a)(1). And an approved food additive isn’t automatically cleared for supplements either. These are different regulatory pathways with different tests; clearing one doesn’t clear the others.

What counts as “chemically altered” is where the ground is least settled. FDA’s guidance describes a range of processing it treats as chemical alteration (using a solvent to pull out constituents ordinary water processing wouldn’t yield, or changing the ingredient’s chemical form, among others), but that guidance is still in draft as of mid-2026, so the term’s precise edges are genuinely disputed within the industry. That uncertainty isn’t a reason to guess; it’s the reason this clause, more than any other, belongs in front of counsel before you commit to an ingredient form.

One more thing the middle bucket makes clear: even when the food-supply exemption removes the notification requirement, it does not remove the safety requirement. The adulteration standard still applies. There must still be a reasonable expectation that the ingredient is safe under the conditions of use in your labeling. Exempt from filing is not the same as exempt from responsibility.

What a safety basis actually has to show

When an ingredient lands in the third bucket, the word “notification” undersells what’s required; this is not a form you file and forget. Under 21 U.S.C. 350b and the regulation at 21 CFR 190.6, it has to contain the information that is the basis on which you concluded the ingredient will reasonably be expected to be safe under the conditions recommended or suggested in your labeling. In plain terms: you are building and submitting a safety case. Verified against the current statute and regulation as of mid-2026, it centers on a few things:

• Who files. The manufacturer or distributor of the new dietary ingredient, or of the supplement that contains it. Not the retailer, and not FDA: it’s not the agency’s job to go find your safety data. In practice the ingredient supplier often holds the data, and who files (and whether a shared “master file” is used) is its own coordination problem.
• The identity. A clear identification of the new dietary ingredient and a description of the supplement or supplements that will contain it, including the conditions of use.
• The safety basis. A history of use or other evidence of safety establishing that the ingredient, at your intended level and conditions, will reasonably be expected to be safe. FDA expects full-text copies of the studies and references relied on, not abstracts, not citations alone, not a link. The safety narrative has to actually carry the conclusion.
• The timing and mechanics. The notification must reach FDA at least 75 days before the ingredient is introduced or delivered for introduction into interstate commerce. The regulation calls for an original and two copies, filed with FDA’s Office of Dietary Supplement Programs; FDA acknowledges receipt, assigns a number, and the 75-day clock runs from that receipt.

The “reasonably be expected to be safe” standard is deliberately not a drug’s “safe and effective.” You aren’t proving the ingredient works; you’re showing a credible basis to expect it won’t hurt anyone at the intended use. But the effort is real: a defensible safety dossier (identity, manufacturing, toxicology, a coherent narrative) is scientific and regulatory work, often done with a consultant or the ingredient supplier, and it’s the part of the timeline that dwarfs the 75-day wait itself.

A notification is not an approval

This is the point brands most often get backwards. Filing an NDI notification does not mean FDA approved your ingredient. There is no approval to get.

FDA’s own position, stated as of mid-2026, is explicit: acceptance of a notification for filing is procedural, and does not constitute a finding by FDA that the ingredient, or the supplement that contains it, is safe or not adulterated. After the 75 days, FDA may send a “no objection” letter, or one raising concerns about identity or safety, or one identifying deficiencies, or one saying the substance isn’t a dietary ingredient at all. A “no objection” letter is the best case, and it is still not an endorsement or a shield: FDA reserves the right to act later if the product turns out to be adulterated or misbranded. You filed; the responsibility for the ingredient’s safety stays entirely with you.

If that sounds familiar, it should. It’s the same structure behind a notification is not an approval, the same way facility registration isn’t: FDA registers facilities and receives notifications, but approves no supplement, label, or ingredient. It’s the same filing-is-not-approval logic behind structure/function claims, where a 30-day notice to FDA is a filing, not a blessing. The pattern holds across the category: the maker is responsible, FDA acts after the fact, and any brand, or manufacturer, advertising an ingredient as “FDA-approved” because a notification was filed has misread the mechanism.

Why NDI status is the timeline surprise, and how to surface it early

Here is where this stops being regulatory trivia and starts being a launch-schedule problem, which is exactly how it shows up on a manufacturing floor.

Play out the bad version. A founder falls for a buzzy new active, locks a formula around it, signs off the bench work, and orders materials. Somewhere near the finish line (a label review, a marketplace question, a cautious lab), someone asks whether the ingredient needed an NDI notification. The answer is yes. Now the launch stops cold: a 75-day statutory waiting period at minimum, and before that, weeks or months of building a safety dossier that doesn’t exist yet. The formula work is done, the money is spent, and the calendar is wrecked, not because anyone made a chemistry mistake, but because a regulatory question got asked in the wrong order. NDI status is one of the quiet long poles in where the real manufacturing timeline comes from, and it’s the one most launch plans never see coming.

Now the good version, which costs nothing extra: you ask the question first. A disciplined shop screens for NDI exposure during feasibility (the paper-and-experience pass that happens before a single sample is mixed) precisely because it’s the cheapest moment to find a problem. If a candidate ingredient looks like it might be a new dietary ingredient, that’s a flag to raise before the bench commits, so your counsel can evaluate it while you still have options: document the grandfathered history, confirm the food-supply exemption, budget the notification into the timeline honestly, or choose a different ingredient form that avoids the question altogether. Hearing “this one may need an NDI notification; check with your counsel before we build around it” at feasibility is the screen doing its job.

That early flag is the role a manufacturer should play. Apollo flags a novel ingredient at feasibility as part of how it runs custom formulation and R&D: if an active looks novel, imported, or newly synthesized, we raise it before the bench commits and coordinate around it, so the regulatory question reaches your counsel while acting on it is still free. What we don’t do is render the legal determination or file the notification: those stay with your counsel and, often, your ingredient supplier, who may hold the safety data.

What’s settled and what’s still moving (as of mid-2026)

One reason NDI questions belong with counsel rather than a checklist is that the rules are still, in part, being written.

The statute is settled and long-standing: the October 15, 1994 line, the adulteration consequence, the food-supply exemption, and the 75-day requirement all sit in the FD&C Act (21 U.S.C. 350b) and the regulation (21 CFR 190.6), verified live as of mid-2026. Those aren’t moving.

FDA’s guidance on how to apply them is another matter. The agency’s central document (“New Dietary Ingredient Notifications and Related Issues,” issued as draft guidance in 2011 and revised in 2016) remains, in most of its parts, draft and nonbinding as of mid-2026. That’s the guidance that tries to pin down the thorny questions, like what counts as “chemically altered” and what a safety dossier must show, which is why those edges stay contested. FDA has finalized only pieces at the margins: a final guidance on notification procedures and timeframes in March 2024, and a further master files draft in April 2024. The core interpretive questions are, for now, answered by a document FDA itself labels not for implementation. The takeaway isn’t to track FDA’s guidance calendar; it’s to treat NDI status as a live question rather than a solved one, and to hand the judgment to a professional who follows it.

A pre-formulation NDI checklist you can run before the bench locks

Run these questions on any ingredient that feels novel, imported, trendy, or “too new to be obvious,” before you build a formula around it. None replaces your counsel’s review; they surface the issues worth bringing to that review while it’s still cheap to act.

• Is this even a dietary ingredient? Vitamin, mineral, herb or botanical, amino acid, a dietary substance to supplement the diet, or a concentrate/extract of one of those. If it doesn’t fit the category, it has a bigger problem than NDI status.
• Was it marketed as a dietary ingredient in the US before October 15, 1994 (and can you prove it)? Not “is it old.” Can you produce documentation of pre-1994 US marketing in this form? An industry “old dietary ingredient” list is a research lead, not proof; FDA doesn’t accept those on their own.
• Is the food-supply exemption really available, in your form? Has the ingredient been present in the US food supply as a food, in a form not chemically altered? Concentration, extraction, or a changed chemical form can forfeit it, and GRAS or food-additive status is a different pathway that doesn’t settle the question.
• If a notification is likely, who holds the safety data, and who files? Often the ingredient supplier. Confirm early whether the data exists and who owns the notification, because that decides your timeline.
• Have you budgeted the time? At minimum a 75-day statutory wait, plus however long the safety dossier takes to build. If that doesn’t fit your launch date, you want to know now.
• Have you asked your counsel, before the formula locks? The point is to reach counsel with time to change course, not to confirm a decision you’ve already committed materials to.

If an ingredient clears these and still feels uncertain, that uncertainty is the signal to get a regulatory professional involved before you build. The cheapest NDI notification is the one you planned for; the most expensive is the one you discovered.

Where your manufacturer fits, and where it stops

You can learn a lot about a contract manufacturer from how it handles a novel ingredient. A shop that builds whatever you hand it (no feasibility screen, no regulatory flag) will happily let an NDI problem surface on your dime, at the worst possible moment. A shop that pauses to say “that one may be a new dietary ingredient; check with your counsel before we design around it” is showing you the discipline you’re actually buying.

That’s the line Apollo works. We screen for a possible NDI at feasibility, coordinate with you and your ingredient supplier on the practical pieces, and build the product once the ingredient path is decided. What we don’t do is act as your regulatory counsel or file your notification: the judgment about whether an ingredient is new, grandfathered, or exempt is a legal determination we’re not the ones to make. We state the division the same way every time: we support; your counsel decides. The regulatory strategy is yours to own; our job is to make sure the question gets asked early enough that owning it doesn’t cost you a launch.

About this information

This article is an educational overview for supplement brands and founders. It is not legal, regulatory, or medical advice, and it does not create any professional or advisory relationship. Laws, regulations, and marketplace policies governing dietary ingredients change frequently and vary by jurisdiction and by where and how a product is sold, and FDA’s guidance on new dietary ingredients remains, in significant part, in draft form. Whether any specific ingredient is a “new dietary ingredient,” is grandfathered, or qualifies for the food-supply exemption is a fact-specific determination. Verify current requirements with qualified legal counsel or a regulatory professional before acting on anything described here. The information is current only as of the review date shown above. Apollo Future Labs supports manufacturing execution (formulation, feasibility screening, testing, and documentation) while your counsel decides your regulatory and compliance strategy.